Molnupiravir

Product Description

Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N⁴-hydroxycytidine (NHC). Molnupiravir competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC₅₀ values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, Molnupiravir improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable.

Solubility

Preparing Stock Solutions for Molnupiravir

The following data is based on the product molecular weight 329.31

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.04 mL	15.18 mL	30.37 mL
5 mM	0.61 mL	3.04 mL	6.07 mL
10 mM	0.30 mL	1.52 mL	3.04 mL
50 mM	0.06 mL	0.30 mL	0.61 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Sheahan An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci.Transl.Med. 2020 PMID: 32253226
• Gordon Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J.Biol.Chem. 2021 PMID: 33989635
• Toots Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci.Transl.Med. 2019 PMID: 31645453